论文部分内容阅读
目的探讨纳洛酮治疗慢阻肺合并呼吸衰竭的临床效果及安全性。方法 78例慢阻肺合并呼吸衰竭患者随机分为2组,2组均给予无创呼吸机通气治疗,研究组在此基础上加用纳洛酮,评价治疗前后肺功能指标(FEV1、FEV1/FVC、FEV1%)改善情况。结果研究组肺功能、血气指标改善效果均优于对照组(P<0.05),总有效率达92.5%,显著高于对照组的81.6%(P<0.05)。结论无创正压通气联合纳洛酮可显著改善慢阻肺合并呼吸衰竭患者肺功能状况,提高治疗效果,且不良反应少,值得推广应用。
Objective To investigate the clinical efficacy and safety of naloxone in the treatment of COPD with respiratory failure. Methods 78 patients with chronic obstructive pulmonary disease and respiratory failure were randomly divided into 2 groups. Both groups were given noninvasive ventilator ventilation. Based on the above results, the study group added naloxone to evaluate the pulmonary function indexes (FEV1, FEV1 / FVC , FEV1%) to improve the situation. Results The improvement of pulmonary function and blood gas indexes in the study group were better than those in the control group (P <0.05). The total effective rate was 92.5%, which was significantly higher than that of the control group (81.6%, P <0.05). Conclusion Noninvasive positive pressure ventilation combined with naloxone can significantly improve lung function in patients with COPD and respiratory failure, improve the therapeutic effect, and less adverse reactions, it is worth popularizing and applying.